# reload+after+2024-01-22 07:44:34.649858
address1§4851 Tamiami Trail N
address2§Suite 200
city§Naples
state§FL
zip§34103
country§United States
phone§239 302 1707
website§https://www.enveric.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
fullTimeEmployees§25
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Joseph Edward Tucker Ph.D.', 'age': 55, 'title': 'CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 825937, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peter J. Facchini Ph.D.', 'age': 59, 'title': 'Chief Innovation Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 332375, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin M. Coveney CPA', 'age': 59, 'title': 'Chief Financial Officer', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
exDividendDate§1208908800
payoutRatio§0.0
beta§0.179
currency§USD
dateShortInterest§1702598400
forwardEps§-3.44
exchange§NCM
quoteType§EQUITY
shortName§Enveric Biosciences, Inc.
longName§Enveric Biosciences, Inc.
firstTradeDateEpochUtc§1430746200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§25d93899-7d3d-3c56-be11-8ed160fe89cc
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§7.0
targetMeanPrice§8.5
targetMedianPrice§8.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§1.02
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
